
Release date: 2024-08-19 15:35:48 Article From: Lucius Laos Recommended: 348
As a novel anti-cancer drug, Selpercatinib can treat solid tumors associated with RET gene mutations. By interfering with key signaling pathways of cancer cells, it effectively slows down the growth of tumors. It is especially suitable for patients who have tried other therapies but have not seen significant results.
Before starting Selpercatinib, it's important to understand some key medication considerations.
Animal studies have shown that Selpercatinib may be harmful to the fetus. Pregnant women should be aware of the potential risks and women of childbearing potential are advised to use effective contraception during treatment and for a week after the last dose. Women with male partners should also follow the same contraceptive recommendations.
Thyroid function needs to be monitored regularly before and during treatment. Thyroid hormone replacement therapy may be used if needed. Depending on the severity of hypothyroidism, medications may need to be suspended or discontinued.
Knowing the indications for Selpercatinib can help patients better understand the therapeutic scope of the drug, and the following are the main indications for the drug.
Selpercatinib is indicated for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or other FDA-approved assay confirmed rearrangement.
Selpercatinib is indicated for the treatment of adult and pediatric patients 2 years of age and older who have an FDA-approved test-confirmed RET gene fusion, have locally advanced or metastatic solid tumors, have progressed on prior systemic therapy, or have no other effective treatment options.
When using Selpercatinib, it is important to be aware of possible adverse effects to use it safely, and here are the side effects to be aware of.
Hyperphosphatemia is an abnormally high level of phosphate in the blood, which can lead to muscle cramps, bone pain, and even negative effects on the kidneys. Patients need to have their blood phosphate levels checked regularly, and their diet or medications to control phosphate levels can prevent and reduce symptoms.
During the course of treatment, patients may experience diarrhea, and frequent bowel movements may lead to dehydration and electrolyte imbalances. To alleviate this symptom, adequate fluid intake should be maintained and antidiarrheal drugs should be used promptly under the guidance of a doctor.
[Warm tips] If you feel any discomfort or have questions during the treatment, please feel free to contact your doctor for timely advice and support.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3512025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5522024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3522025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3262025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3012025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643